Indication: Urothelial Cancer

Retrospective Observational Study to Assess the Efficacy of Anti-PD-(L)1 Treatment in Subjects with Fibroblast Growth Factor Receptor Aberrations

FGFR aberration-positive

Sub-indication: Urothelial Carcinoma with FGFR Mutation

Line of Therapy: Must have received treatment with at least 1 anti PD- (L)1.

Observational

Principal Investigator: Arash Rezazadeh, M.D.
Norton Cancer Institute

Sponsor: Janssen Research & Development

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.